Condensed Consolidated Statements of Changes in Stockholders' Equity - 9 months ended Sep. 30, 2015 - USD ($) $ in Thousands	BioRx, LLC Common stock	BioRx, LLC Diplomat Pharmacy, Inc. Shareholders' Equity	BioRx, LLC	Burman's Apothecary, LLC Common stock	Burman's Apothecary, LLC Diplomat Pharmacy, Inc. Shareholders' Equity	Burman's Apothecary, LLC	Common stock	Additional Paid-in Capital	Retained Earnings	Diplomat Pharmacy, Inc. Shareholders' Equity	Noncontrolling Interest	Total
Balance at the beginning of the period at Dec. 31, 2014							$ 148,901	$ 9,893	$ 5,354	$ 164,148	$ 4,579	$ 168,727
Balance at the beginning of the period (in shares) at Dec. 31, 2014							51,457,023					51,457,023
Changes in shareholders' deficit
Net income									22,210	22,210	(742)	$ 21,468
Proceeds from public offering, net of issuance costs							$ 187,238			187,238		187,238
Proceeds from public offering, net of issuance costs (in shares)							6,821,125
Repurchase of stock options							$ (34,194)	(2,104)		(36,298)		(36,298)
Stock issued upon stock option exercises							$ 11,516	(2,771)		8,745		8,745
Stock issued upon stock option exercises (in shares)							1,683,000
Excess tax benefits related to share-based awards								14,348		14,348		14,348
Issuance of common stock as partial consideration in acquisition	$ 125,697	$ 125,697	$ 125,697	$ 9,578	$ 9,578	$ 9,578
Issuance of common stock as partial consideration in acquisition (in shares)	4,038,853			253,036
Share-based compensation expense								2,502		2,502		2,502
Balance at the end of the period at Sep. 30, 2015							$ 448,736	$ 21,868	$ 27,564	$ 498,168	$ 3,837	$ 502,005
Balance at the end of the period (in shares) at Sep. 30, 2015							64,253,037					64,253,037